BioNTech SE
BNTXPrice data temporarily unavailable. Please refresh.
About BioNTech SE
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Frequently Asked Questions
What is the stock price of BioNTech SE (BNTX) today?▼
Price data for BioNTech SE (BNTX) is temporarily unavailable. This may occur outside of market hours or during periods of high data provider load.
What is the market cap of BioNTech SE?▼
Market capitalization data for BioNTech SE is temporarily unavailable.
What is the P/E ratio of BioNTech SE stock?▼
P/E ratio data for BioNTech SE is temporarily unavailable.
What exchange is BioNTech SE stock listed on?▼
BioNTech SE (BNTX) is listed on the NASDAQ. NASDAQ is a US electronic stock exchange known for technology and growth companies, and is the second-largest exchange in the world by market capitalization. BioNTech SE operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry.
What is the analyst consensus price target for BioNTech SE?▼
The consensus analyst price target for BioNTech SE (BNTX) is $123.22. Analyst price targets represent forward-looking estimates with significant uncertainty. They should not be interpreted as investment advice or a guarantee of future performance.
How to Analyze BioNTech SE Stock
Analyzing a stock like BioNTech SE (BNTX) requires evaluating both quantitative metrics and qualitative factors. The quantitative analysis starts with valuation multiples: the P/E ratio compares the stock price to earnings per share and is most useful when benchmarked against the company's historical average and sector peers. The price-to-sales (P/S) ratio is particularly useful for high-growth companies where earnings may be suppressed by reinvestment.
Beyond valuation, investors examine growth metrics: revenue growth rate, earnings per share (EPS) growth, and free cash flow generation. A company that consistently grows revenue and EPS while generating strong free cash flow has more financial flexibility to invest in new products, return capital to shareholders through buybacks and dividends, and weather economic downturns without requiring external financing.
As a company in the HEALTHCARE sector — specifically the BIOTECHNOLOGY industry, BioNTech SE is subject to sector-specific risks and valuation conventions that differ from the broader market. Sector rotation, regulatory changes, and macroeconomic conditions affect HEALTHCAREstocks differently than the overall S&P 500.
Technical analysts also track moving averages as trend indicators. The 50-day moving average for BioNTech SE is currently $94.85, and the 200-day moving average is $99.77.
Recent quarterly results show revenue growth of -35.4% year-over-year and earnings growth of -43.2% year-over-year. The net profit margin stands at -44.6%, which is a measure of how efficiently the company converts revenue into net income.